| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
3-O-Methyl-D-glucopyranose is a substrate for glucose transporters and has been used to measure responses of jejunal and ileal short circuit currents to determine maximal transport capacity and carrier affinity in studies of intestinal glucose transport. The compound does not have a defined pharmacological target but serves as a tool for studying glucose transport mechanisms.
|
|---|---|
| ln Vitro |
In vitro, 3-O-Methyl-D-glucopyranose is used as a biochemical reagent for life science research. It is often used in glycosylation studies, carbohydrate chemistry, and as a reference compound in the synthesis of complex sugar derivatives. The compound is also used to study carbohydrate interactions, glycoproteins, and the structural study of carbohydrates in biological systems. It has been used to measure intestinal glucose transport in vitro.
|
| ln Vivo |
In vivo, 3-O-Methyl-D-glucopyranose has been used in studies to assess intestinal glucose transport in rats with diabetes mellitus. Varying concentrations of the compound were used to measure responses of jejunal and ileal short circuit currents to determine maximal transport capacity and carrier affinity. The compound serves as a non-metabolizable glucose analog for studying glucose transport in vivo.
|
| Enzyme Assay |
For in vitro transport assays, 3-O-Methyl-D-glucopyranose is used as a substrate for glucose transporters. Cells expressing glucose transporters are incubated with the compound at various concentrations, and uptake is measured using radiolabeled or fluorescent detection methods. The compound is also used in electrophysiological studies to measure short circuit currents in intestinal tissue preparations.
|
| Cell Assay |
For in vitro cell-based experiments, 3-O-Methyl-D-glucopyranose is used to study glucose transport in cultured cells. Cells are treated with the compound at concentrations ranging from 0.1-10 mM for various time periods, and cellular uptake is measured. The compound can also be used in competitive inhibition studies with D-glucose to assess transporter specificity and affinity.
|
| Animal Protocol |
For in vivo animal studies, 3-O-Methyl-D-glucopyranose is administered to rodents (typically rats) via oral gavage or intraperitoneal injection. Intestinal segments (jejunum and ileum) are mounted in Ussing chambers, and short circuit currents are measured in response to varying concentrations of the compound to determine maximal transport capacity and carrier affinity. This model is used to assess intestinal glucose transport in diabetes mellitus.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3-O-Methyl-D-glucopyranose are characterized in the context of glucose transport studies. The compound has a molecular weight of 194.18 g/mol and is water-soluble (90 mg/mL). As a non-metabolizable glucose analog, it is transported by glucose transporters but is not extensively metabolized. It is primarily used as a tracer for studying glucose transport rather than as a drug candidate.
|
| Toxicity/Toxicokinetics |
3-O-Methyl-D-glucopyranose is a research chemical and should be handled with appropriate laboratory safety precautions. As a sugar derivative, it is generally considered to have low toxicity. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a well-ventilated area.
|
| Additional Infomation |
3-O-Methyl-D-glucopyranose (CAS 13224-94-7) is primarily a research-grade biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are in glycosylation studies, carbohydrate chemistry, and as a reference compound in the synthesis of complex sugar derivatives. It is also used to study carbohydrate interactions, glycoproteins, and the structural study of carbohydrates in biological systems. It has been used to assess intestinal glucose transport in rats with diabetes mellitus. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C7H14O6
|
|---|---|
| Molecular Weight |
194.18
|
| Exact Mass |
194.079
|
| CAS # |
13224-94-7
|
| PubChem CID |
83246
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
406.3±45.0 °C at 760 mmHg
|
| Melting Point |
167-169 °C(lit.)
|
| Flash Point |
199.5±28.7 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.548
|
| LogP |
-2.67
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
163
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CO[C@H]1[C@@H]([C@H](O[C@@H]([C@@H]1O)O)CO)O
|
| InChi Key |
SCBBSJMAPKXHAH-OVHBTUCOSA-N
|
| InChi Code |
InChI=1S/C7H14O6/c1-12-6-4(9)3(2-8)13-7(11)5(6)10/h3-11H,2H2,1H3/t3-,4-,5-,6+,7+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-4-methoxyoxane-2,3,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (514.99 mM)
DMSO: ≥ 50 mg/mL (257.49 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL | |
| 5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL | |
| 10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
